

B1
Cornea'd

24. The method of claim 14, there the at least one eye cell is a corneal endothelium cell, photoreceptor cell, bipolar cell, ganglion cell, or oculomotor cell.

25. The method of claim 14, wherein the sequence permitting expression of the gene is a Rous Sarcoma Virus promoter, E1A promoter, or MLP promoter.

26. The method according to claim 21, wherein the at least one region needed to replicate in the eye cell is an E1A or E1B region.--

REMARKS

Upon entry of this Preliminary Amendment, claims 14-26 will be pending in the application. Support for these claims is found throughout the specification, See, for example, pages 5-11.

Applicants do not believe that entry of this Preliminary Amendment requires payment of a fee, or an extension of time. However, please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Steven P. O'Connor
Reg. No. 41, 225

Dated: November 12, 2001

0696797.4130
FDETT 4649866

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000